NASDAQ:IMUX
Immunic Inc. Stock News
$1.27
-0.0200 (-1.55%)
At Close: May 21, 2024
Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity
06:30am, Friday, 06'th Aug 2021
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chro
Immunic, Inc. to Participate in Investor Conferences in August
06:30am, Tuesday, 03'rd Aug 2021
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chroni
Immunic, Inc. Announces Closing of $45.0 Million Public Offering
04:01pm, Monday, 19'th Jul 2021
NEW YORK, July 19, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on
Why Immunic Plummeted by 21% on Thursday
06:04pm, Thursday, 15'th Jul 2021
Word of a new share issue made investors feel queasy.
Immunic Stock Is Trading Lower After Equity Raise Of $45M To Fund Lead Pipeline Candidates
09:43am, Thursday, 15'th Jul 2021
Immunic Inc (NASDAQ: IMUX) has priced an underwritten public offering of 4.5 million shares at $10 per share, representing a discount of about 16% from the last close price of $11.89 on Wednesday. T
IMUX Stock Falls Over 20% Pre-Market: Why It Happened
09:14am, Thursday, 15'th Jul 2021
The stock price of Immunic Inc (NASDAQ: IMUX) fell by over 20% pre-market. This is why it happened.
Immunic, Inc. Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 14'th Jul 2021
NEW YORK, July 14, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused o
NEW YORK, July 12, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chro
Immunic Stock Jumps As FDA Signs Off On 2 Clinical Trial Applications
11:07am, Thursday, 01'st Jul 2021
The FDA has signed off Immunic Inc's (NASDAQ: IMUX) investigational new drug application for the Phase 3 ENSURE program of lead asset IMU-838 in patients with relapsing-remitting multiple sclerosis
IMUX Stock Price Increases Over 5% Pre-Market: Why It Happened
07:31am, Thursday, 01'st Jul 2021
The stock price of Immunic, Inc. (NASDAQ: IMUX) increased by over 5% pre-market. These are the details.
NEW YORK, July 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflam
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
06:30am, Monday, 28'th Jun 2021
NEW YORK, June 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chroni
Immunic, Inc. to Participate in Industry and Investor Conferences in June
06:30am, Thursday, 10'th Jun 2021
NEW YORK, June 10, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chroni
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
06:30am, Tuesday, 01'st Jun 2021
NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
06:30am, Thursday, 06'th May 2021
NEW YORK, May 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic infla
